Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Share-based Compensation (2016 - 2025)

Apyx Medical (APYX) has disclosed Share-based Compensation for 15 consecutive years, with $500000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 40.33% year-over-year to $500000.0, compared with a TTM value of $2.0 million through Dec 2025, down 50.14%, and an annual FY2025 reading of $2.0 million, down 50.14% over the prior year.
  • Share-based Compensation was $500000.0 for Q4 2025 at Apyx Medical, down from $530000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.7 million in Q2 2022 and bottomed at $451000.0 in Q1 2025.
  • Average Share-based Compensation over 5 years is $1.1 million, with a median of $1.2 million recorded in 2021.
  • The sharpest move saw Share-based Compensation skyrocketed 42.91% in 2022, then tumbled 60.02% in 2025.
  • Year by year, Share-based Compensation stood at $1.3 million in 2021, then increased by 22.37% to $1.6 million in 2022, then tumbled by 44.3% to $914000.0 in 2023, then decreased by 8.32% to $838000.0 in 2024, then plummeted by 40.33% to $500000.0 in 2025.
  • Business Quant data shows Share-based Compensation for APYX at $500000.0 in Q4 2025, $530000.0 in Q3 2025, and $520000.0 in Q2 2025.